OTCM
FOGCF
Market cap0USD
Apr 21, Last price
0.00USD
Name
Avisa Diagnostics Inc
Chart & Performance
P/E
0.00
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
110.26%
Revenues
278k
-67.63%
Net income
-716k
L-82.69%
CFO
-452k
L-66.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Avisa Diagnostics Inc., a clinical-stage medical device company based in Santa Fe, New Mexico, is dedicated to developing the Avisa BreathTest. This innovative drug/device biomarker technology platform is designed for the ultra-rapid identification of virulent bacterial pathogens and the subsequent monitoring of bacterial load. The system works by analyzing a patient's breath after they have inhaled or ingested Avisa's proprietary drug substrates. The company has already established clinical proof-of-concept through trials in conditions such as cystic fibrosis, tuberculosis, and community-acquired pneumonia, and is now concentrating on pivotal trials for Post-COVID-19 bronchiectasis and ventilator-associated pneumonia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2020‑12 | 2019‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | ||
Unusual Expense (Income) | ||
NOPBT | ||
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | ||
Net income | ||
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | ||
BB yield | ||
| Debt | ||
Debt current | ||
Long-term debt | ||
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | ||
| Cash flow | ||
Cash from operating activities | ||
CAPEX | ||
Cash from investing activities | ||
Cash from financing activities | ||
FCF | ||
| Balance | ||
Cash | ||
Long term investments | ||
Excess cash | ||
Stockholders' equity | ||
Invested Capital | ||
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | ||
Price | ||
Market cap | ||
EV | ||
EBITDA | ||
EV/EBITDA | ||
Interest | ||
Interest/NOPBT | ||